Health & Fitness
Health and Fitness
Health and Fitness
Tue, July 26, 2011
Mon, July 25, 2011 Acorda Therapeutics to Host Conference Call to Discuss Second Quarter 2011 Financial Results on August 1, 2011
HAWTHORNE, N.Y.--([ BUSINESS WIRE ])--Acorda Therapeutics, Inc. (Nasdaq: [ ACOR ]) announced today that it will host a conference call and live audio webcast to report its financial results for the second quarter of 2011 on Monday, August 1, 2011 at 8:30 a.m. ET.
To participate in the conference call, please dial 866-770-7146 (domestic) or 617-213-8068 (international) and reference the access code 27646709. The presentation will be available via a live webcast at:
[ phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=194451&eventID=4155738 ]
A replay of the call will be available from 11:30 a.m. ET on August 1, 2011 until midnight on August 30, 2011. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 98995716. The archived webcast will be available for 30 days in the Investor Relations section of the Acorda website at [ www.acorda.com ].
About [ Acorda Therapeutics ]
Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders. The Company is commercializing and marketing [ AMPYRA® (dalfampridine ]) Extended Release Tablets, 10 mg, in the Unites States. AMPYRA is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS); this was demonstrated by an improvement in walking speed. AMPYRA was developed using Elana™s Matrix Drug Absorption System (MXDAS®) technology and is manufactured by Elan based on a supply agreement with Acorda.
Acorda also markets [ ZANAFLEX CAPSULES® (tizanidine hydrochloride) ], a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Ampyra in the United States and to successfully market Zanaflex Capsules; third party payors (including governmental agencies) may not reimburse for the use of Ampyra at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of Ampyra outside of the United States and our dependence on our collaboration partner Biogen Idec in connection therewith; competition; failure to protect Acorda Therapeuticsa™ intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; the ability to obtain additional financing to support Acorda Therapeutics' operations; and, unfavorable results from our preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
